Journal of Hepatology最新文献_第10页

The etymology of liver in ancient Greek and Latin 古希腊语和拉丁语中 "肝 "的词源

IF 26.8 1区医学

Journal of Hepatology Pub Date : 2025-02-01 DOI: 10.1016/j.jhep.2024.09.042

John Henry , Marvad Ahad

引用次数: 0

Thyroid hormone receptor-β analogues for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) 治疗代谢功能障碍相关性脂肪性肝炎（MASH）的甲状腺激素受体-β类似物

IF 26.8 1区医学

Journal of Hepatology Pub Date : 2025-02-01 DOI: 10.1016/j.jhep.2024.10.018

Vlad Ratziu , Thomas S. Scanlan , Eveline Bruinstroop

{"title":"Thyroid hormone receptor-β analogues for the treatment of metabolic dysfunction-associated steatohepatitis (MASH)","authors":"Vlad Ratziu , Thomas S. Scanlan , Eveline Bruinstroop","doi":"10.1016/j.jhep.2024.10.018","DOIUrl":"10.1016/j.jhep.2024.10.018","url":null,"abstract":"<div><div>The association between suboptimal thyroid function ((sub)clinical hypothyroidism or low-normal thyroid function) and the metabolic syndrome and MASLD (metabolic dysfunction-associated steatotic liver disease) has been clearly established. Furthermore, in MASLD, intracellular thyroid hormone concentrations are low and the activation of the thyroid hormone receptor (THR) is reduced. Administration of thyroid hormone has been shown to reduce liver triglycerides by stimulating fatty acid disposal through lipophagy and beta-oxidation, and to lower LDL-cholesterol. As thyroid hormone exerts its effects in many different organs, including the heart and bone, several drug candidates have been developed as selective thyromimetics for the THR-β nuclear receptor with potent and liver-targeted activity. Importantly, these compounds have reduced affinity for the THR-α nuclear receptor and tissue distribution profiles that differ from endogenous thyroid hormones, thereby reducing unwanted cardiovascular side effects. The most advanced compound, resmetirom, is an oral drug that demonstrated, in a large phase III trial in patients with MASH (metabolic dysfunction-associated steatohepatitis), the ability to reduce liver fat, decrease aminotransferase levels and improve atherogenic dyslipidaemia with a good tolerability profile. This translated into histological improvement that led to accelerated approval of this drug for active fibrotic steatohepatitis, a milestone achievement as a first MASH drug.</div></div>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"82 2","pages":"Pages 375-387"},"PeriodicalIF":26.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142450256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Publisher’s note on “The risk-benefit assessment of liver biopsy in times of non-invasive screening for liver fibrosis” by Ivana Ilic and Tamara Milovanovic [J Hepatol 73 (2020) 701–702] 伊万娜-伊利奇（Ivana Ilic）和塔玛拉-米洛瓦诺维奇（Tamara Milovanovic）撰写的 "无创肝纤维化筛查时期肝活检的风险效益评估"[J Hepatol 73 (2020) 701-702] 出版人注释

IF 26.8 1区医学

Journal of Hepatology Pub Date : 2025-02-01 DOI: 10.1016/j.jhep.2024.09.028

引用次数: 0

Gut bacterial membrane components as pathogenic signalling molecules in PSC-IBD 肠道细菌膜组分在PSC-IBD中的致病信号分子作用

IF 26.8 1区医学

Journal of Hepatology Pub Date : 2025-02-01 DOI: 10.1016/j.jhep.2024.11.024

David C. Trampert

引用次数: 0

Synergy between public health policy and clinicians plays a key role in reducing fracture risk in patients with viral hepatitis 公共卫生政策与临床医生之间的协同作用在降低病毒性肝炎患者骨折风险方面发挥着关键作用。

IF 26.8 1区医学